Bevacizumab has been sold as Avastin by originator Roche for many years and used by the NHS for various forms of cancer, with ...

That scuppered Sanofi's plans for filing tolebrutinib in PPMS, and the FDA has now slammed the brakes on its efforts to get ...

Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...

To begin to close the equity gap in diabetes, we must commit to designing therapies that account for the practical realities ...

Life science marketing is changing, and with it our need for personalised engagement strategies. While omnichannel marketing ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Vinay Patel, an innovative pharmacist who's set out to ...

The French pharma major has started a $15.50 per share cash tender offer for Emeryville, California-based Dynavax, which ...

The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of an oral formulation of ...

People in life sciences companies understand how patents are crucial to their business, by setting competitive boundaries, ...

In labs, water consumption and single-use plastics like pipette tips can contribute to environmental impact. Lab equipment ...

AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US in light of FDA concerns over clotting complications – including deaths – in people taking the drug.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tarek Samad, Lundbeck’s senior vice president and head ...